NYSE:DVA - Davita Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$59.14 +0.04 (+0.07 %)
(As of 02/20/2019 02:56 AM ET)
Previous Close$59.10
Today's Range$58.11 - $59.68
52-Week Range$48.25 - $79.11
Volume1.72 million shs
Average Volume1.68 million shs
Market Capitalization$9.82 billion
P/E Ratio16.57
Dividend YieldN/A
Beta1.31
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
CUSIP23918K10
Phone303-405-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.40 billion
Cash Flow$7.8644 per share
Book Value$26.66 per share

Profitability

Net Income$663.61 million

Miscellaneous

Employees74,500
Market Cap$9.82 billion
OptionableOptionable

Davita (NYSE:DVA) Frequently Asked Questions

What is Davita's stock symbol?

Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will Davita's stock buyback program work?

Davita declared that its Board of Directors has initiated a stock buyback program on Wednesday, October 11th 2017, which permits the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board of directors believes its stock is undervalued.

How were Davita's earnings last quarter?

Davita Inc (NYSE:DVA) released its quarterly earnings data on Wednesday, February, 13th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.01. The business earned $2.82 billion during the quarter, compared to analysts' expectations of $2.97 billion. Davita had a return on equity of 13.75% and a net margin of 1.40%. Davita's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 EPS. View Davita's Earnings History.

When is Davita's next earnings date?

Davita is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Davita.

What price target have analysts set for DVA?

8 analysts have issued 1-year price objectives for Davita's stock. Their predictions range from $59.00 to $70.00. On average, they expect Davita's share price to reach $64.5733 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price. View Analyst Price Targets for Davita.

What is the consensus analysts' recommendation for Davita?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Davita.

Has Davita been receiving favorable news coverage?

News headlines about DVA stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Davita earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Davita's key competitors?

Who are Davita's key executives?

Davita's management team includes the folowing people:
  • Mr. Kent J. Thiry, Chairman & CEO (Age 63)
  • Mr. Joel Ackerman, Chief Financial Officer (Age 54)
  • Mr. James K. Hilger, Chief Accounting Officer (Age 57)
  • Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)
  • Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48)

Who are Davita's major shareholders?

Davita's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.79%), Dimensional Fund Advisors LP (1.55%), Gates Capital Management Inc. (1.34%), Oregon Public Employees Retirement Fund (1.13%), Jarislowsky Fraser Ltd (1.11%) and Bank of New York Mellon Corp (1.10%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.

Which major investors are selling Davita stock?

DVA stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, Partner Fund Management L.P., Consulta Ltd, Bank of New York Mellon Corp, Manning & Napier Group LLC, Two Sigma Investments LP and KBC Group NV. Company insiders that have sold Davita company stock in the last year include Charles Berg, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.

Which major investors are buying Davita stock?

DVA stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Oregon Public Employees Retirement Fund, DPM Capital LLC, Caption Management LLC, Gates Capital Management Inc., Toronto Dominion Bank, First Trust Advisors LP and State of Tennessee Treasury Department. View Insider Buying and Selling for Davita.

How do I buy shares of Davita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Davita's stock price today?

One share of DVA stock can currently be purchased for approximately $59.14.

How big of a company is Davita?

Davita has a market capitalization of $9.82 billion and generates $11.40 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.57 on an earnings per share basis. Davita employs 74,500 workers across the globe.

What is Davita's official website?

The official website for Davita is http://www.davita.com.

How can I contact Davita?

Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]


MarketBeat Community Rating for Davita (NYSE DVA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  388 (Vote Outperform)
Underperform Votes:  422 (Vote Underperform)
Total Votes:  810
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel